Parexel

Last updated
Parexel International
Company type Private
Industry Clinical research organizations
Pharmaceutical
Founded1982
Headquarters Durham, North Carolina, U.S. Newton, Massachusetts, U.S.
Number of locations
84+ facilities in 51+ countries
Key people
CEO: Jamie Macdonald
Services clinical trial management, data management, medical writing, biostatistics, pharmacovigilance, regulatory consulting
RevenueIncrease2.svg$2.3 billion (2017) [1]
Number of employees
18,900 [2]
Website parexel.com

Parexel International is an American provider of biopharmaceutical services. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. [3] The company publishes the annual Parexel R&D Statistical Sourcebook [4] and operates the Parexel-Academy. [5]

Contents

Parexel was founded in 1982 by Josef von Rickenbach [6] and organic chemist Anne B. Sayigh [7] initially to advise Japanese and German firms on how to navigate the FDA approval process. [8] The firm has grown organically over the years and through 40 acquisitions. Josef von Rickenbach is credited with establishing Parexel's culture and practices based on the principles he experienced as a researcher at Schering-Plough in Lucerne, Switzerland, before leaving the company upon retiring in 2018. [8]

In 1990, the firm expanded internationally and established new practice areas. By 1999 it had a staff of 4,500 and 45 offices. [8] In the 2000s, it grew to over 18,000 employees. Parexel's consulting and clinical trial work has helped establish many household drug brands and contributed to numerous successes in modern pharmacology.[ citation needed ]

The company was acquired by private equity firm Pamplona Capital Management for approximately $5.0 billion. [9] The deal closed in September 2017. [10] On July 2, 2021, Parexel announced a merger agreement under which it would be acquired by EQT IX fund and Goldman Sachs for $8.5 billion. [11] EQT and Goldman Sachs completed the acquisition on November 15, 2021. [12]

Acquisition history

TGN1412 clinical trial

In March 2006, a Parexel-run trial on behalf of TeGenero, the now bankrupt German biotechnology firm, on its anti-inflammatory drug TGN1412 to treat rheumatoid arthritis, multiple sclerosis or leukaemia, caused severe inflammation and multiple organ failure in six healthy volunteers at a facility based at Northwick Park Hospital in London. [46] The drug had been tested on animals but this was the first test on humans.

Parexel became the target of legal proceedings from lawyers representing the injured volunteers after the insurance policy of TeGenero was unable to provide sufficient compensation. When the liable company [47] subsequently declared bankruptcy, [48] lawyers for the volunteers initiated legal proceeding against Parexel and the two parties later entered into talks; [49] the results of this meeting have not been made public. [50]

A documentary shown in the UK on 28 September 2006 featuring journalist Brian Deer as part of Channel 4's Dispatches series exposed uncertainty about the existence of data that should mandatorily have been submitted by TeGenero to the Medicines and Healthcare products Regulatory Agency (MHRA) prior to the trial indicating whether TGN1412 had been adequately tested on human blood in vitro. Concerns were also raised about whether a safe human dosage was properly obtained by TeGenero. The MHRA however concluded that none of the companies involved could be held responsible for the outcome of the test and that the adverse events that occurred were most likely caused by an unpredicted biological action of the drug in humans. [51]

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">Labcorp Drug Development</span> Contract research organization

Labcorp Drug Development is a contract research organization headquartered in Burlington, North Carolina, providing nonclinical, preclinical, clinical and commercialization services to pharmaceutical and biotechnology industries. Formerly called Covance, the company is part of Labcorp, which employs more than 70,000 people worldwide.

Bausch Health Companies Inc. is an American-Canadian multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. Bausch Health's business model is primarily focused on acquiring small pharmaceutical companies and then sharply increasing the prices of the drugs these companies sell.

<span class="mw-page-title-main">Charles River Laboratories</span> American biotechnology and pharmaceutical corporation

Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry and offers support in the fields of basic research, drug discovery, safety and efficacy, clinical support, and manufacturing.

IMS Health was an American company that provided information, services and technology for the healthcare industry. IMS stood for Intercontinental Medical Statistics. It was the largest vendor of U.S. physician prescribing data. IMS Health was founded in 1954 by Bill Frohlich and David Dubow with Arthur Sackler having a hidden ownership stake. In 2010, IMS Health was taken private by TPG Capital, CPP Investment Board and Leonard Green & Partners. The company went public on April 4, 2014, and began trading on the NYSE under the symbol IMS. IMS Health was headquartered in Danbury, Connecticut.

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

IQVIA, formerly Quintiles and IMS Health, Inc., is an American Fortune 500 and S&P 500 multinational company serving the combined industries of health information technology and clinical research. IQVIA is a provider of biopharmaceutical development, professional consulting and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including investment strategy and management consulting services. It has a network of more than 88,000 employees in more than 100 countries and a market capitalization of US$49 billion as of August 2021. As of 2023, IQVIA was reported to be one of the world's largest contract research organizations (CRO).

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American healthcare company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories. Before a merger with National Health Laboratory in 1995, the company operated under the name Roche BioMedical. Labcorp performs its largest volume of specialty testing at its Center for Esoteric Testing in Burlington, North Carolina, where the company is headquartered. As of 2018, Labcorp processes 2.5 million lab tests weekly.

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin.

A contract manufacturing organization (CMO), more recently referred to as a contract development and manufacturing organization (CDMO) to avoid the acronym confusion of Chief Medical Officer or Clinical Monitoring Organization in the pharma industry, is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major pharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing instead.

WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.

<span class="mw-page-title-main">Dechra Pharmaceuticals</span> Pharmaceutical Company based in UK

Dechra Pharmaceuticals plc is a business involved in the development and marketing of veterinary products based in Northwich, England. It is listed on the London Stock Exchange until it was acquired by EQT Partners in January 2024.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Medidata Solutions is an American technology company that develops and markets software as a service (SaaS) for clinical trials. These include protocol development, clinical site collaboration and management; randomization and trial supply management; capturing patient data through web forms, mobile health (mHealth) devices, laboratory reports, and imaging systems; quality monitor management; safety event capture; and monitoring and business analytics. Headquartered in New York City, Medidata has locations in China, Japan, Singapore, South Korea, the United Kingdom, and the United States.

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals

Indegene Limited is a company offering research and development and management services to healthcare and pharmaceutical enterprises. It was founded in 1998 and is based in Bangalore, India.

WIL Research Laboratories, LLC was a contract research organization (CRO), privately held for 40 years, that provided product safety toxicological research, metabolism, bioanalytical, pharmacological, and formulation services to the pharmaceutical, biotechnology, chemical, agrochemical, and food products industries, as well as manufacturing support for clinical trials. WIL Research was well-known internationally in many disciplines, and considered by many industry experts to be the premier laboratory in the world for developmental and reproductive toxicology (DART).

ICON plc is an Irish headquartered Nasdaq listed multinational healthcare intelligence and clinical research organisation that provides consulting, clinical development and commercialisation services for the pharmaceutical industry. As of June 2023, ICON had approximately 41,160 employees in 108 locations spread across 53 countries.

Omnicell, Inc. is an American multinational healthcare technology company headquartered in Mountain View, California. It manufactures automated systems for medication management in hospitals and other healthcare settings, and medication adherence packaging and patient engagement software used by retail pharmacies. Its products are sold under the brand names Omnicell and EnlivenHealth.

References

  1. ↑ "PAREXEL International Reports Fourth Quarter and Fiscal Year 2017 Results" (Press release). 28 August 2017.
  2. ↑ "PAREXEL – Our Company" . Retrieved 29 March 2023.
  3. ↑ "MoneyShow.com: TOP PROS' TOP PICKS – Parexel Puts Drugs on Trial". MoneyShow.com. Archived from the original on 2016-04-01. Retrieved 2015-09-30.
  4. ↑ "PAREXEL Biopharmaceutical Statistical Sourcebook 2014/2015 (eStats)" . Retrieved 29 March 2023.
  5. ↑ Applied Clinical Trials Editorial Staff (13 April 2015). "PAREXEL Academy Adds Programs for Students".
  6. ↑ "List of Public Companies Worldwide, Letter – Businessweek – Businessweek". Businessweek.com. 30 June 2023.
  7. ↑ "Entrepreneur Briefs".
  8. 1 2 3 "Josef von Rickenbach – Parexel". Bilanz.ch.
  9. ↑ "BRIEF-Pamplona Capital Management completes acquisition of Parexel". Reuters. 29 September 2017.
  10. ↑ "Pamplona Capital Management acquires Parexel International | Private Equity Wire". Private Equity Wire. 2017-10-02. Retrieved 2021-01-29.
  11. 1 2 "Parexel to be Acquired by EQT Private Equity and Goldman Sachs Asset Management | Parexel International Corporation". newsroom.parexel.com. Retrieved 2022-01-04.
  12. 1 2 "EQT Private Equity and Goldman Sachs Asset Management Complete Acquisition of Parexel | Parexel International Corporation". newsroom.parexel.com. Retrieved 2022-01-04.
  13. 1 2 "PAREXEL Form 10-K (1997)". EDGAR . PAREXEL. 1997-09-29. Retrieved 2016-12-25.
  14. ↑ "PAREXEL COMPLETES TWO ACQUISITIONS". PRNewswire UK. PAREXEL. 1997-03-03. Retrieved 2016-12-25.
  15. ↑ "PAREXEL Announces Information Technology Investments". PRNewswire . PAREXEL. 1997-11-06. Retrieved 2016-12-25.
  16. ↑ "PAREXEL Completes Acquisition of Kemper-Masterson, Inc". PRNewswire . PAREXEL. 1997-12-02. Retrieved 2016-12-25.
  17. ↑ "PAREXEL Acquires Leading International Contract Marketing Services Company". PRNewswire . PAREXEL. 1998-03-02. Retrieved 2016-12-25.
  18. ↑ Bulkeley, William M. (1998-03-03). "Parexel Pays $148 Million For Three European Firms". The Wall Street Journal . ISSN   0099-9660 . Retrieved 2016-12-25.
  19. ↑ "PAREXEL Acquires Groupe Pharmedicom". PRNewswire . PAREXEL. 1999-04-01. Retrieved 2016-12-25.
  20. ↑ "COVANCE SAYS IT IS ACQUIRING PAREXEL FOR $612 MILLION". The New York Times . 1999-04-30. Retrieved 2016-12-25.
  21. ↑ "Covance, Parexel part". CNNMoney . 1999-06-25. Retrieved 2016-12-25.
  22. ↑ "PAREXEL Acquires the Phase I Clinical Research Business And Bioanalytical Laboratory of CEMAF S.A." PRNewswire . PAREXEL. 1999-09-15. Retrieved 2016-12-25.
  23. ↑ "PAREXEL Acquires Majority Interest in Clinical Pharmacology Research Business and Bioanalytical Laboratory in South Africa". PRNewswire . PAREXEL. 2000-10-16. Retrieved 2016-12-25.
  24. ↑ "Parexel acquires Glaxo's UK pharmacology unit". www.drugdiscoveryonline.com. 2000-10-04. Retrieved 2016-12-25.
  25. ↑ "PAREXEL International Enhances Presence in Latin America". PRNewswire . PAREXEL. 2001-07-30. Retrieved 2016-12-25.
  26. ↑ "PERCEPTIVE INFORMATICS ACQUIRES INVANTAGE, INC". PAREXEL. 2002-09-10. Retrieved 2016-12-25.
  27. ↑ "Parexel acquires Pracon & HealthIQ". Boston Business Journal . American City Business Journals. 2002-11-04. Retrieved 2016-12-25.
  28. ↑ "ACQUISITIONS AND IMPACT OF RESTRUCTURING AND OTHER CHARGES". PAREXEL Form 10-K (2003). EDGAR. 2003-09-15. Retrieved 2016-12-25.
  29. 1 2 "NOTE 18. SUBSEQUENT EVENTS". Parexel Form 10-K 2005. EDGAR. 2005-09-08. Retrieved 2016-12-25.
  30. ↑ "Parexel acquires marketing firm". Boston Business Journal . American City Business Journals. 2004-10-04. Retrieved 2016-12-25.
  31. ↑ "Parexel buys out remaining minority interest in Perceptive Informatics". Boston Business Journal . American City Business Journals. 2005-08-22. Retrieved 2016-12-25.
  32. ↑ "Parexel Establishes Presence in India". pharmaasia.com. Contineo Media Pte Ltd (Singapore). 2006-10-04. Retrieved 2016-12-25.
  33. ↑ "PAREXEL Agrees to Acquire California Clinical Trials Medical Group, Inc., and Behavioral and Medical Research, LLC; Acquisition Adds West Coast Phase I Unit and Specialty Phase II – IV Clinical Research Services". www.edgemontcapital.com/. Edgemont Capital Partners. 2006-10-12. Retrieved 2016-12-25.
  34. ↑ "Parexel strengthens Asia-Pacific hand with Apex acquisition". pharmatimes.com. PharmaTimes Media Ltd. 2007-10-02. Retrieved 2016-12-25.
  35. ↑ "Parexel puts up $182M for U.K. firm ClinPhone". Boston Business Journal . American City Business Journals. 2008-06-13. Retrieved 2016-12-25.
  36. ↑ "PAREXEL International Announces Acquisition of Liquent, Inc., and Updates Financial Guidance". [PR Newswire]. Cision Inc. 2012-12-27. Retrieved 2016-12-25.
  37. ↑ "Parexel Acquires Heron Group in Up To $38M Deal". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. 2013-05-01. Retrieved 2016-12-25.
  38. ↑ Brennan, Zachary (2014-07-02). "Parexel taps Middle East, North Africa with Atlas acquisition". outsourcing-pharma.com. William Reed Business Media . Retrieved 2016-12-25.
  39. ↑ "Parexel acquires ClinIntel". Cosmetics Business. HPCi Media Ltd. 2014-10-06. Retrieved 2016-12-25.
  40. ↑ Brennan, Zachary (2015-03-26). "Parexel to tap additional pharmacovigilance services with QSI acquisition". outsourcing-pharma.com. William Reed Business Media . Retrieved 2016-12-25.
  41. ↑ Garde, Damian (2016-01-21). "Parexel moves to buy a pharma consulting firm". FierceBiotech. Questex. Retrieved 2016-12-25.
  42. ↑ "PAREXEL to Acquire ExecuPharm". Contract Pharma. Rodman Media. 2016-09-27. Retrieved 2016-12-25.
  43. ↑ "Parexel Completes Purchase of Roam Analytics' Natural Language Processing Capability". Parexel. 2020-09-22. Retrieved 2020-09-22.
  44. ↑ "Parexel Announces Acquisition of Leading Pharmacology Modeling & Analytics Firm Model Answers". www.parexel.com. Retrieved 2021-06-10.
  45. ↑ "Announcing Calyx: Advancing Clinical Research Through Technology-Enabled Services" . Retrieved 29 March 2023.
  46. ↑ "Drugs trial men 'seriously ill'". BBC News . March 15, 2006.
  47. ↑ "When drug trials go horribly wrong". The International Herald Tribune. April 9, 2006. Retrieved 2007-12-18.
  48. ↑ "Will Parexel Settle? TeGenero Litigation". ClinPage. March 19, 2007. Retrieved 2007-12-18.
  49. ↑ "Window is open for compensation in TGN1412 case". PharmaTimes. March 14, 2007. Archived from the original on January 31, 2013. Retrieved 2007-12-18.
  50. ↑ "FirstWord Pharma". firstwordpharma.com.
  51. ↑ Clinical trial final report, MHRA Archived 2006-12-06 at the Wayback Machine , 25 May 2006
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.